Drug Profile
Research programme: neurodegenerative disorder therapeutics - TauTaTis
Alternative Names: TTT-3002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator TauTaTis
- Class Small molecules
- Mechanism of Action LRRK2 protein inhibitors; Protein kinase inhibitors; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Cancer; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)